Will others avoid 'patent dance' after Sandoz court win?
This article was originally published in Scrip
Executive Summary
With a California district court siding with Novartis unit Sandoz last week that it did nothing wrong by not engaging in the disclosure and dispute resolution process laid out by the Biologics Price Competition and Innovation Act (BPCIA) – the law that established the abbreviated licensure pathway for biosimilars – the ruling may spur other companies to do the same.